卡培他滨及替吉奥联合紫杉醇治疗弥漫型晚期胃癌的疗效分析  

Clinical Effect of Paclitaxel Combined with Capecitabine or with S-1 as First-line Treatment for Diffuse Type of Advanced Gastric Cancer Patients

作　　者：柳婧美[1] 白威[1] 纪丕军[1] 王山川[1] 张丽娟[1] 陈永静[1] 程文华[1] 樊凡[1] 杨迁妮[1] 马久红[2] 

机构地区：[1]山西省肿瘤医院消化三科,山西太原030013 [2]山西省人民医院神经外科,山西太原037018

出　　处：《解放军药学学报》2016年第3期284-287,共4页Pharmaceutical Journal of Chinese People's Liberation Army

摘　　要：目的对比卡培他滨联合紫杉醇与替吉奥联合紫杉醇治疗弥漫型晚期胃癌患者的疗效。方法收集山西省肿瘤医院2009年6月至2015年6月之间54例弥漫型晚期胃癌患者病例,其中卡培他滨联合紫杉醇治疗方案28例,替吉奥联合紫杉醇治疗26例,观察患者的总生存期及无进展生存期情况。采用Kaplan Meier描绘生存曲线;Log-rank法检验生存期。结果弥漫型晚期胃癌患者接受卡培他滨联合紫杉醇化疗方案的中位生存时间为9.5个月（95%CI：7.9～11.0个月）,接受替吉奥联合紫杉醇化疗方案的中位生存时间为10.5个月（95%CI：9.5～11.5个月）。接受卡培他滨联合紫杉醇化疗方案的中位无进展生存期为5.4个月（95%CI：4.3～6.5个月）,接受替吉奥联合紫杉醇化疗方案的中位无进展生存期为7.0个月（95%CI：6.7～7.3个月）。采用Kaplan Meier描绘生存曲线。经Log-rank法检验弥漫型晚期胃癌患者接受替吉奥联合紫杉醇方案的总生存期、无进展生存期显著短于卡培他滨联合紫杉醇方案（P〈0.05）。结论弥漫型晚期胃癌患者接受替吉奥联合紫杉醇方案可获得更多生存获益。Objective To compare the efficacy of capecitabine combined with paclitaxel and S-1 combined with paclitaxel in the treatment of patients with advanced gastric cancer of the diffuse type. Methods We collected 54 cases of the diffuse type of advanced gastric cancer treated in Shanxi Cancer Hospital between June 2009 and June 2015.28 of the cases were treated with capecitabine combined with paclitaxel and 26 with by S-1 combined with paclitaxel. The overall survival （OS） and progression free survival （ PFS ） of the two groups were observed. Results The median OS was 9.5 months （ 95% CI ： 7.9 - 11.0, months） in the capecitabine combined group and 10.5 months in the S-1 combined group（95% CI：9.5 - 11.5 months）. The median PFS was 5.4 months （95%CI：4.3 -6.5 months） in the capecitabine combined group and 7.0 months in the S-1 combined group （95% CI：6.7 -7.3 months）. Survival curves were calculated by Kaplan Meier analysis. Analyzed by the long-rank test, the OS and PFS of the diffuse type of patients in the S-1 combined group were significantly shorter than those of capecitabine combined group （ P 〈 0.05 ）. Conclusion The diffuse type of patients should receive S-1 combined with paclitaxel, which is of more benefit to survival.

关 键 词：晚期胃癌 Lauren分型 化疗 

分 类 号：R969.4[医药卫生—药理学]